The Switching Antiplatelet-9 (SWAP-9) Study

• Status: RECRUITING
• Trial end date: 2027-02-28

Summary

The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).

• Phase: PHASE4

Details

• Lead Sponsor: University of Florida
• Treatments: Aspirin; Clopidogrel; Prasugrel Hydrochloride